“Exemptia – World’s first biosimilar of Adalimumab”
EXEMPTIA is a prescription medicine that can be self-injected. It is used to treat moderate to severe rheumatoid arthritis (RA). EXEMPTIA is grouped within a class of medications called biologic response modifiers, or biologics. By working on the immune system, biologics block proteins that contribute to the disease process. Because EXEMPTIA suppresses the immune system, patients are at a greater risk for getting serious infections. Exemptia has been researched, developed and produced by scientists at the Zydus Research Centre. The biosimilar is the first to be launched by any company in the world and is a ‘fingerprint match’ with the originator in terms of safety, purity and potency of the product. The biosimilar of Adalimumab is a part of Zydus’ robust biologics programme which has the largest number of monoclonal antibodies under development in India. The group’s R&D pipeline which comprises 15 biologics includes biosimilars and two novel biologics. These biologics are being developed to treat auto immune disorders like arthritis, cancer, infertility and stroke.